ゲイン・セラピューティクスに関するコメント

$ゲイン・セラピューティクス(GANX.US)$ Gain Therapeutics Announces Positive Results From the Single Ascending Dose (Sad) Part of the Phase 1 Clinical Trial of GT-02287, a Novel Gcase-Targeting Small Molecule Therapy for Gba1 Parkinson’s Disease

$ゲイン・セラピューティクス(GANX.US)$
NEWS
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Positive results from the SAD part of the Phase 1 Clinical Trial of GT-02287.
GT-02287 was well tolerated with no serious adverse events.
Achieved appropriate plasma exposure levels after oral administration.
GT-02287 has the potential to slow or stop Parkinso...

$ゲイン・セラピューティクス(GANX.US)$ EXCLUSIVE: Gain Therapeutics Tells Benzinga 'Data Support the Ability of GT-02287 to Prevent Several Steps in the Disease Cascade Resulting From GCase Misfolding and Dysfunction'

$ゲイン・セラピューティクス(GANX.US)$ Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease
7 MINUTES AGO, 2:00 PM EST
VIA GLOBENEWSWIRE

$ゲイン・セラピューティクス(GANX.US)$Moomoo 24/7· 1 min ago
Gain Therapeutics Announces Preclinical Data Demonstrating GT-02287 Restored Motor Function In Mouse Models Of Parkinson's Disease

$ゲイン・セラピューティクス(GANX.US)$ EOY OR 1Q 2024 Upcoming Milestones ● Completion of the single ascending dose part of the Phase 1 clinical trial of GT-02287 expected late Q4 or early Q1 2024, with demonstration of safety and tolerability of GT-02287 after single administration. ● Completion of the multiple ascending dose part of the Phase 1 clinical trial of GT-02287 expected in Q2 2024, with demonstration of safety...

$ゲイン・セラピューティクス(GANX.US)$ loaded here, their potential is enormous

$ゲイン・セラピューティクス(GANX.US)$ watching

Upgrades
• $カスタマーズ・バンコープ(CUBI.US)$ : KBW Upgrades to Outperform from Market Perform - PT $80 (from $72)
• $フォーティネット(FTNT.US)$ : Barclays Upgrades to Overweight from Equalweight - PT $395 (from $364)
• $Hoegh LNG(HMLP.US)$ : Stifel Upgrades to Buy from Hold - PT $9.50 (from $8)
• $Randolph Bancorp(RNDB.US)$ : Compass Point Upgrades to Buy from Neutral - PT $27 (from $23)
• $サイトワン・ランドスケープ・サプライ(SITE.US)$ : UBS Upgrades to Neutral from Sell - PT $165 (fr...